ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
ICON and LEO Pharma join forces on clinical trial mission
This news article, published on PharmaTimes online, indicates how the collaboration will concentrate on launching and running studies within medical dermatology.
LEO Pharma, ICON partner to advance clinical trials in dermatology
This news article covers the strategic partnership between LEO Pharma and ICON to propel clinical trial execution within medical dermatology.
Strategies for building greater DE&I in Rare Disease trials
This article describes some factors that produce barriers in the rare disease drug development process and identifies strategies to improve diversity in these trials.
Optimising biotech trial designs to stretch your cash runway
Brandon Early discusses how optimising trials designs at the earliest stages can help innovative biotech companies to maximise their available capital.
As clinical trials face a hiring crunch, here’s how research organisations can pivot
Helen Yeardley, Senior Vice President, Global Clinical Operations, discusses how ICON is adapting to the global shortage of Clinical Research Associates in the industry.
The significant increase in demand for Clinical Research Associates (CRAs)
Helen Yeardley, Senior Vice President, Clinical Operations, offers her insights on the role that a Clinical Trial Associate (CRA) plays in the clinical trial process.
Pivotal time for CROs': ICON CEO Cutler on changing APAC trial trends
Steve Cutler and Atsushi Ogawa discuss the increased opportunity for decentralised trials, in addition to the challenges and opportunities in Asia Pacific.
This article reflects on the progress that has been made in decentralised and hybrid clinical trials in the last number of years.
Historical Controls in Rare Disease drug development: Using RWE to overcome key challenges
This article explores the advantages of using Historical Controls, as well as several considerations for their effective use.
Fortifying vaccines through disease surveillance and data reporting
In this article, McLendon explores the topic of fortifying vaccines against future pandemics.